Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
How many of your eligible patients are yet to be offered protection against shingles?
-
Understand who your eligible patients are 1. Ensure you are identifying and recalling patients eligible for a shingles vaccination using your call and recall system.
Eligibility for the Shingles National Immunisation Programme:
For more information on severely immunocompromised individuals, visit our dedicated pages:
For more information on the eligibility criteria for the Shingles National Immunisation Programme refer to the Greenbook chapter 28a1.
2. Identify eligible patients by setting up alerts and searches using your patients’ Electronic Health Records
Are you struggling to identify eligible patients in your practice?
Ensure you are identifying and recalling patients eligible for a shingles vaccination using your call and recall system.![]( "$titleDesktopImage")
![]( "$titleMobileImage")
Visit Illuminate, GSK’s dedicated community-driven platform designed by Immunisation Leads, for support with identifying your practice’s eligible patients†:
†The system searches have been developed by GSK in partnership with Interface Clinical Services. They do not make clinical decisions and are not intended to replace individual clinical judgement of the HCP using the search outputs. Clinical review is required of the lists created.
As you call patients in for dedicated vaccination clinics across winter, how can you also plan for shingles clinics?
During winter, some of your patients attending clinics may be eligible for non-seasonal shingles vaccination. Seize this opportunity to:
1. Proactively call and recall all eligible patients and book them in for their 1st and 2nd dose
2. Discuss the value of vaccination against shingles and the importance of completing both doses
3. Answer any questions your patients may have, and share helpful patient resources![]( "$titleDesktopImage")
![]( "$titleMobileImage")
Use the eligibility checker on Illuminate, to find out in minutes if your patient is eligible for shingles vaccination, inputting only your patients date of birth and health status:
-
Plan dedicated shingles clinics How many of your eligible patients have been vaccinated against shingles so far?
More of your patients become eligible for the shingles vaccination each week, and remain unprotected until they receive their vaccination.
Why run dedicated clinics?
Running dedicated clinics all year round can be an effective way to ensure eligible patients are consistently being booked in for their shingles vaccination. These patients may otherwise have been missed if relying solely on opportunistic vaccinations.
Your proactive planning can help to protect your eligible patients from shingles.
![]( "$titleDesktopImage")
![]( "$titleMobileImage")
Did you know?
In the first 5 years since a shingles vaccine was introduced in England (including the National Immunisation Programme with ZostavaxⓇ), there were 45,000 fewer GP consultations and 1,840 fewer hospitalisations for shingles and post-herpetic neuralgia.2
Through effective implementation of the Shingles National Immunisation Programme, you may reduce the burden of herpes zoster and post-herpetic neuralgia on your practice.
Guidance to run your dedicated clinics
Are you running dedicated clinics to vaccinate your patients against shingles? Or perhaps you could find gaps in existing clinics? Are there ways you could make vaccination as easy as possible with coffee mornings, community centres or mid week clinics?
Visit illuminate, GSK’s dedicated community-driven platform designed by Immunisation Leads, to learn from experts who are effectively implementing the Shingles National Immunisation Programme.
Seize the opportunity to ensure you are helping to protect your eligible patients from shingles, by planning dedicated shingles clinics this winter.
![]( "$titleDesktopImage")
![]( "$titleMobileImage")
Did you know?
In addition to item of service payments, the Shingles National Immunisation Programme earns Quality and Outcomes Framework (QOF) points2,3
![]( "$titleDesktopImage")
![]( "$titleMobileImage")
Visit Illuminate for a step-by-step comprehensive checklist on how to deliver the Shingles National Immunisation Programme
-
Ensure sufficient SHINGRIX stock Vaccines for the Shingles National Immunisation Programme are centrally procured and available to order via ImmForm. Ensure your GP surgery has sufficient stock for planned clinics along with any opportunistic vaccinations.
-
Proactively invite all patients who have received their 1st dose of SHINGRIX for their 2nd dose SHINGRIX is given as a 2 dose schedule1,4,5. The national guidance for administration of the 2nd dose as part of the National Immunisation Programme differs from the SPC.
The 2nd dose of SHINGRIX is a requirement for course completion, and is not a booster.
In the ZOE-50 and ZOE-70 clinical trials, most study participants received both doses of SHINGRIX6,7.
Use the 1st Dose Search Files every week and filter for those that need their 2nd dose.
A 4-fold increase in cellular immune response was observed following the 2nd dose of SHINGRIX vs after the 1st dose only**, in adults ≥60 years in a single-blind study8.
The same results were first published in Chlibeck et al. Vaccine. The graph has been independently created by GSK from the original data.
**Phase 2, single-blind, randomised controlled study in adults ≥60 years. One of the study groups (N=146) assessed immunogenicity following each dose of SHINGRIX (2 doses, 2 months apart). Median gE-specific CD4+ T cell expressing at least two activation markers per 10 cells (Q1, Q3) was 122.18 (62.3-290.22) at baseline, 382.57 (236.79-615.51) at month 1 after dose, and 1755.39 (1210.8-2987.71) at 1 month after dose 2.
-
Raise awareness of shingles and the opportunity for vaccination with your patients Ensure members of the public are aware of:
- The Shingles National Immunisation Programme
- Their eligibility for vaccination
- The potential risks of shingles
Raising awareness with patients is an essential step when implementing the programme, and GSK have a range of programme awareness materials available to order.
When discussing the shingles vaccination with your patients, it’s key that patients understand the disease burden of shingles and the value of shingles vaccination, and that you are taking the time to answer any questions they may have.
Order the below to ensure patients are aware of both SHINGRIX doses and are remembering to return, so that no patient misses out on their 2nd dose.
Materials to educate your patients:
Materials to support your patients with taking ownership for their course completion:
References:
- DH Green Book: Ch28a Shingles (Mar 2024)
- Shingles Vaccination Programme GP toolkit for improving uptake, August 2023 (england.nhs.uk). Available at: https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2023/10/Shingles-GP-toolkit-3.pdf. Accessed July 2024
- NHS England. Quality and outcomes framework guidance for 2023/2024, version 2. Available at: https://www.england.nhs.uk/long-read/quality-and-outcomes-framework-guidance-for-2023-24/. Accessed July 2024
- SHINGRIX. Summary of Product Characteristics (GB)
- SHINGRIX, Northern Ireland Summary of Product Characteristics (SPC)
- Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
- Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
- Chlibeck R et al., Vaccine. 2014 Mar;32(15):1745-53. Including web appendix table 1. Available at: https://www.sciencedirect.com/science/article/pii/S0264410X14000516?via%3Dihu b#sec0080
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2023 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
July 2024 | PM-GB-SGX-WCNT-230025 (V3.0)
